Levodopa/Carbidopa/Entacapone Arrow

Levodopa/Carbidopa/Entacapone, the active ingredient in Levodopa/Carbidopa/Entacapone Arrow, is a combination drug presented as an oral tablet for oral use. It is employed to manage Parkinson's disease by increasing dopamine availability in the brain of adult patients, helping to reduce motor symptoms such as tremor, rigidity, and bradykinesia.

GNH USA supplies Levodopa/Carbidopa/Entacapone Arrow as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide, ensuring consistent quality, reliable delivery, regulatory compliance across multiple markets and competitive pricing globally.

Levodopa/Carbidopa/Entacapone is used in the management of Parkinson's disease and its motor complications, providing enhanced dopaminergic therapy through combined mechanisms. - Parkinson's disease (early stage): improves tremor, rigidity, and bradykinesia. - Parkinson's disease with motor fluctuations: reduces OFF periods and extends ON time. - Parkinson's disease requiring combination therapy: offers comprehensive dopaminergic support. - Parkinson's disease with dyskinesia: helps balance dopaminergic stimulation. - Parkinson's disease after deep brain stimulation: provides adjunctive symptom control.

Levodopa/Carbidopa/Entacapone may be associated with a range of adverse reactions.

Common Side Effects: - Nausea: an upset stomach that may be mild to moderate in intensity. - Dizziness: sensation of light‑headedness, especially when standing quickly. - Headache: pressure or throbbing pain that can vary in severity. - Insomnia: difficulty falling or staying asleep, sometimes accompanied by vivid dreams.

Serious or Rare Side Effects: - Dyskinesia: involuntary, erratic movements that can affect limbs and facial muscles. - Hallucinations: visual or auditory perceptions without external stimulus, often in older patients. - Severe hypotension: marked drop in blood pressure leading to fainting or falls. - Allergic reactions: rash, itching, swelling, or angioedema that may require immediate medical attention.

Before initiating therapy, several safety considerations should be reviewed. - Monitor blood pressure: watch for orthostatic hypotension, especially during dose titration. - Assess liver function: entacapone may affect hepatic enzymes; periodic testing is advised. - Review psychiatric history: patients with prior psychosis may be more prone to hallucinations. - Adjust dose in renal impairment: consider renal function when determining dosing frequency. - Avoid abrupt discontinuation: sudden cessation can worsen Parkinsonian symptoms. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Levodopa/Carbidopa/Entacapone can interact with several medication classes.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis due to excessive catecholamine levels. - Antipsychotics that block dopamine receptors: may diminish therapeutic effect and worsen Parkinsonism. - High‑dose COMT inhibitors or other levodopa formulations: can lead to severe dyskinesia.

Moderate Interactions (Monitor Closely): - Alpha‑adrenergic blockers: may potentiate orthostatic hypotension. - Anticholinergic agents: can increase central side effects such as confusion. - Iron or vitamin B6 supplements: may reduce levodopa absorption; separate dosing times.